Aerovate Therapeutics (AVTE) Competitors $9.51 +0.70 (+7.95%) As of 07/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUSShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Its Competitors Enliven Therapeutics Structure Therapeutics Cidara Therapeutics Ardelyx Praxis Precision Medicines ProKidney Collegium Pharmaceutical Akebia Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Aerovate Therapeutics (NASDAQ:AVTE) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Do institutionals and insiders believe in AVTE or ELVN? 95.1% of Enliven Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate AVTE or ELVN? Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, AVTE or ELVN? Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-5.59Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80 Which has more volatility and risk, AVTE or ELVN? Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Is AVTE or ELVN more profitable? Enliven Therapeutics' return on equity of -31.84% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Enliven Therapeutics N/A -31.84%-30.09% Does the media prefer AVTE or ELVN? In the previous week, Enliven Therapeutics had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Enliven Therapeutics and 0 mentions for Aerovate Therapeutics. Enliven Therapeutics' average media sentiment score of 0.71 beat Aerovate Therapeutics' score of 0.00 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Enliven Therapeutics Positive SummaryEnliven Therapeutics beats Aerovate Therapeutics on 9 of the 12 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$275.65M$816.22M$5.54B$9.41BDividend YieldN/A4.84%3.75%4.03%P/E Ratio-3.181.2021.0120.09Price / SalesN/A25.49433.8199.01Price / CashN/A19.5636.1658.27Price / Book2.406.878.125.65Net Income-$75.52M-$4.17M$3.25B$257.91M7 Day Performance-9.60%0.03%0.97%2.09%1 Month Performance14.72%2.12%7.36%11.13%1 Year Performance-85.07%2.14%31.31%18.40% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$9.51+7.9%N/A-86.7%$275.65MN/A-3.1820High Trading VolumeELVNEnliven Therapeutics2.8636 of 5 stars$23.00+2.4%$41.20+79.1%-1.8%$1.13BN/A-11.9850News CoverageGPCRStructure Therapeutics2.9436 of 5 stars$19.57+2.9%$76.17+289.2%-49.1%$1.12BN/A-22.49136CDTXCidara Therapeutics3.6939 of 5 stars$55.32+9.5%$57.29+3.6%+331.6%$1.12B$1.27M-1.8890Positive NewsHigh Trading VolumeARDXArdelyx4.1637 of 5 stars$4.61+2.7%$10.89+136.2%-21.4%$1.10B$333.61M-20.9590Analyst RevisionPRAXPraxis Precision Medicines2.4592 of 5 stars$53.60+6.1%$94.11+75.6%-0.3%$1.09B$8.55M-5.00110News CoverageAnalyst ForecastAnalyst RevisionPROKProKidney3.4049 of 5 stars$3.69-18.7%$5.67+53.6%+53.0%$1.08B$306K-6.153Analyst ForecastGap UpHigh Trading VolumeCOLLCollegium Pharmaceutical4.4186 of 5 stars$32.83+1.0%$43.75+33.3%+1.0%$1.05B$631.45M26.91210Positive NewsAKBAAkebia Therapeutics3.7148 of 5 stars$3.97+1.0%$6.75+70.0%+175.2%$1.04B$160.18M-18.90430AMPHAmphastar Pharmaceuticals4.3171 of 5 stars$21.95+1.3%$32.33+47.3%-45.0%$1.03B$731.97M7.952,028RCUSArcus Biosciences2.3406 of 5 stars$9.66+3.5%$21.29+120.5%-39.0%$1.02B$258M-2.30500 Related Companies and Tools Related Companies Enliven Therapeutics Competitors Structure Therapeutics Competitors Cidara Therapeutics Competitors Ardelyx Competitors Praxis Precision Medicines Competitors ProKidney Competitors Collegium Pharmaceutical Competitors Akebia Therapeutics Competitors Amphastar Pharmaceuticals Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
